StockData
Turn Therapeutics Inc. logo

Turn Therapeutics Inc. (TTRX) company profile

TTRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/30
$8.55+0.00 (0.00%)

Close on Nov 17, 2026Market cap $254.69MP/E –Yield –

About Turn Therapeutics

Pharmaceutical Preparations, SIC 2834

Turn Therapeutics Inc. develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. Its lead investigational drug candidate, GX-03, targets moderate-to-severe eczema and onychomycosis using a polyhexanide formulation. The company also develops medical devices based on this formulation for acute wound management, dermatitis care, and antimicrobial wound dressings. Additionally, it conducts exploratory research on a thermostable intranasal vaccine platform. The company's business model centers on licensing its medical devices to commercial healthcare partners, including Medline and MiMedx, while directing internal resources toward clinical drug development.

The company is based in Westlake Village, California, and is incorporated in Delaware. It operates primarily within the United States, where it conducts clinical trials, while preparing foundational clinical activities in select international jurisdictions. Turn Therapeutics relies on a lean internal workforce alongside third-party contractors, vendors, and commercial distribution partners to carry out its development and manufacturing activities.

Summary of the business section of Turn Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Turn Therapeutics Inc.
Headquarters
Westlake Village, CA
Address
250 North Westlake Blvd., #210 91362
Phone
(818) 564-4011
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, Whippany, New Jersey

Stock & identifiers

Ticker
TTRX
Exchange
Nasdaq
IPO date
Oct 8, 2025
Shares outstanding
30M, Aug 12, 2026
Filer category
<br>Emerging growth company
SEC CIK
2023016
CUSIP
90021W105
ISIN
US90021W1053
FIGI
BBG002QTLH75
Share class FIGI
BBG002QTLH84
EIN
32-0456090

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Bradley Evan BurnamChief Executive Officer, Director15,416,260
Neilesh Shailesh GhodadraChief Medical Officer, Director10,000
Zuraiz ChaudharySee Remarks12,500
Kent Edward KesterDirector10,000
Andrew GengosDirector10,000
Martin William DewhurstDirector21,882
Arthur F. GoldenDirector360,602

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsTotalvs. prior year
Bradley Burnam
Chief Executive Officer
$465.74K$186.30K–$652.04K+52%
Zuraiz Chaudhary
Interim Chief Financial Officer
$152.21K$30.40K$1.24M$1.43M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 8, 2025
Offer price
$11.65
Securities offered
17,868,760
Gross proceeds
$208.17M
Exchange
Nasdaq
Lock-up ends (est.)
Apr 6, 2026

“2025, we commenced an offering of common stock under the exemption from registration provided by Tier 2 of Regulation A under the Securities Act of 1933, as amended (the “Securities Act”) at a public offering price of $11.65 per share, which concluded on June 27, 2025.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Oct 8, 2025IPOInitial public offering priced (424B4 prospectus)
Sep 30, 2025Name changeName changed from Global Health Solutions, Inc to Turn Therapeutics Inc.
Sep 29, 2025ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?